Autologous Haematopoietic Stem Cell Transplant (AHSCT) for MS


What is MS Research Australia’s position on AHSCT?

Autologous haematopoietic stem cell transplant (AHSCT, also known as bone marrow transplant) is an immunosuppressive chemotherapy treatment combined with reinfusion of blood stem cells to help re-build the immune system. It has been used to treat a small percentage of people with multiple sclerosis (MS) in Australia and internationally.

MS Research Australia deeply understands and fully acknowledges that people with MS will wish to explore all potential avenues of treatment. AHSCT is playing a role in the range of treatments available to treat MS, however, in order for this to become a standard therapy in Australian clinics and hospitals for people with MS, further rigorous evidence for the effectiveness, safety and most appropriate use of AHSCT is still required. Hospitals must also be able to weigh up the evidence for the relative risks and benefits when making decisions regarding the provision of such treatments in an affordable and equitable manner. Currently the treatment is provided in Australia through two observational clinical trials and by a limited number of centres on a case by case basis. As each person’s situation is unique and as MS Research Australia does not have a direct role in the treatment of MS, it cannot recommend any specific treatment for people living with MS. Decisions about any MS treatments, taking into consideration the potential benefits, risks and side effects for an individual’s particular circumstances, should be made in careful consultation with each individual’s neurologist.

MS Research Australia has worked with Australian haematologists, neurologists and members of the research and MS communities to develop a position statement on the use of AHSCT for MS with guidance on its possible place within the range of treatment options for MS. This position statement has been developed with reference to the current data published in the international peer-reviewed scientific literature – an overview of this data is discussed below.

You can download the MS Research Australia AHSCT Position Statement here

What is Autologous Haematopoietic Stem Cell Transplant (AHSCT)?


Haematopoietic stem cells are a type of adult stem cell found in the blood and bone marrow. Haematopoietic stem cells are able to generate new blood and immune cells. Autologous haematopoietic stem cell transplant (AHSCT) used for MS is similar to the chemotherapy treatment used to treat blood cancers – chemotherapy is used to eliminate the immune system, and then the blood and immune system are restored, in this case, using the patient’s own (autologous) blood stem cells. The aim is to ‘re-boot’ the immune system so that the self-reactive immune cells that are attacking an individual’s nervous system are removed, and replaced with the regenerated immune system, which is thought to be more ‘self-tolerant’ and less likely to continue attacking the body. The stem cells are not thought to contribute to repair of the nervous system, but are primarily used to restore the blood and immune system following the immuno-suppressive chemotherapy treatment.

AHSCT is an intensive form of treatment which involves a number of steps, including:

  1. Pre-treatment to release bone marrow stem cells into the blood
  2. Collecting or ‘harvesting’ the AHSCs from the blood of the patient
  3. Freezing (cryopreserving) the AHSCs in the laboratory until they are required
  4. Administering immuno-chemotherapy to remove the patient’s current immune system (conditioning)
  5. Returning the thawed AHSCs to the patient by infusion into the vein.
  6. Supportive medical treatment is provided in the immediate period following transplant when there is a high risk of infection and bleeding disorders due to the intense immune suppression.

What type of chemotherapy is used in AHSCT for people with MS?

A number of different types of immuno-chemotherapy protocols have been used to treat MS and other autoimmune diseases over the years. Protocols involving busulphan or whole body irradiation are considered too toxic and are generally no longer used for the treatment of autoimmune diseases2. The two protocols that are currently most commonly used for people with autoimmune conditions in Australia, and other countries, are the myeloablative (e.g. BEAM-ATG) and the non-myeloablative (e.g. Cyclophosphamide-ATG) chemotherapy protocols.

Myeloablative refers to the complete removal (ablation) of the immune cells circulating in the blood as well as stem cells resident in the bone marrow. Re-infusion (transplant) of the patient’s stored stem cells is essential in these circumstances to re-establish the immune system. The intense immune suppression of the procedure can be associated with severe and potentially life-threatening complications mainly due to infections. BEAM-ATG is an example of this form of chemotherapy.

Non-myeloablative refers to the removal of the immune cells circulating in the blood, with the bone marrow stem cells being largely unaffected. In these circumstances, re-infusion of the patient’s stem cells is a ‘supportive’ therapy that enables faster recovery of the immune system. The term ‘low intensity’ is sometimes also used to describe this form of chemotherapy, however, this protocol does still cause significant immune suppression and side-effects that may be life-threatening. Cyclophosphamide-ATG is an example of a non-myeloablative regimen.

Reduced Intensity Conditioning is a term usually only used in allogeneic stem cell (stem cells derived from a donor) transplantation for blood cancers. It describes a class of chemotherapy regimens that sit somewhere between the myeloablative and non-myeloablative regimens. It usually refers to the use of a lower dose of the same chemotherapy agents that would be used for myeloablative regimens. They cause immune suppression of varying degrees and duration, and would generally always be supported with stem cell infusion. One published study has described the use of ‘a reduced-intensity BEAM-like conditioning regimen’ in people with MS11, however, this is not widely used in the treatment of people with MS.

The different immuno-chemotherapy regimens are associated with different types of toxicities and risks and the choice of regimen will depend on the patient and the centre conducting the treatment (see more below on risks and side effects experienced in studies of AHSCT for MS). The international evidence on which form of chemotherapy is safest and most effective for people with MS is still accumulating1,2, however, the European Bone Marrow Transplant Autoimmune Disease Working Party recommended the BEAM-ATG conditioning regimen for the treatment of MS in their guidelines published in 20122.

The details of the conditioning regimens used at centres within Australia and internationally can vary considerably. It is important for individuals considering AHSCT for MS to discuss the relative risks and benefits of the particular treatment regimen being offered in relation to their individual circumstances with their healthcare team.  It is also important that the treatment is provided at a centre which has suitable accreditation and that the centre has experience in providing AHSCT for individuals with autoimmune conditions1,3.

What is known about the efficacy of AHSCT to treat MS?

Despite AHSCT having been used in the treatment of blood cancers for several decades, and despite several hundred people with MS having received this form of treatment internationally, it is still considered ‘experimental’ for the treatment of MS as its safety and efficacy has not yet been tested in sufficiently large gold-standard, randomised controlled trials specifically for MS and in comparison to currently available MS therapies.

A number of observational case series of patients undergoing AHSCT for severe MS have been published in the peer-reviewed scientific literature over the last 10 to 15 years. The results of these studies have been variable but similar themes are emerging1,7,19. Generally the outcomes have shown that people who are younger and who still have active inflammatory disease (new lesions on MRI scans and/or relapses) may achieve better outcomes for reducing or stopping disease activity. While disability appears to stabilise, or in some cases improve, in many people with relapsing remitting disease, the majority of the studies show that recovery from more long standing disability is unlikely and disability continues to accumulate. See more details below on the large published European case series1 and a number of smaller observational studies and clinical trials.

To date in Australia, AHSCT has been used at a number of different centres to treat around 50 people with MS who had not responded to standard MS therapies. The results from the Australian patients are yet to be published, but the data, including longer-term follow-up data, is currently being collected and analysed by the individual haematology centres involved and also in a combined approach by the Australian AHSCT MS Registry.

What is known about the safety of AHSCT to treat MS?

The intense immune suppression associated with chemotherapy can leave people vulnerable to severe infections and bleeding in the immediate period following the procedure, which may be life-threatening and require intensive medical support. However, advances in supportive care have seen the mortality risk decline in recent years. Experience with AHSCT in Australian patients, the majority of whom are treated for blood cancers, suggests that AHSCT has a transplant related mortality (TRM) rate of around 1% in the immediate 100 days following transplant4.  The large European case series of AHSCT in people with autoimmune diseases recorded an average TRM of 1.3% for people with MS treated between the years 2001 and 20077. A number of different chemotherapy regimens were included in this series7. Some recent, but smaller, published studies have not recorded any deaths 6,8,9,10,11. No transplant related deaths have been recorded at the Australian centres that have provided this treatment to people with MS (unpublished data, Australian MS AHSCT Registry and the Australasian Bone Marrow Transplant Recipients Registry4).

Despite the decline in mortality from the procedure, the risk of infections from bacteria, viruses and fungi, that would not normally affect people with an intact immune system, remains significant. These infections can result in prolonged hospital stays and, in some cases, may be associated with worse neurological outcomes5,10, 20. Experience with treating blood cancers over many years, as well as autoimmune disorders, suggests that there may also be longer term adverse effects of HSCT, such as effects on other organs, including heart liver, kidney and bone health, reduction in fertility, secondary cancers and secondary autoimmunity5.  In a USA study, the use of ATG in the conditioning regimen was associated with a 2% risk of secondary autoimmunity, particularly of the thyroid15.

The risks of AHSCT will differ depending on the form of chemotherapy used and this should be discussed with the treating haematology centre.

Further details from published studies on AHSCT for MS

The European Bone Marrow Transplant Register (EBMTR)
The EBMTR has published a large case series of AHSCT provided for autoimmune disease between 1996 and 2007 including 345 people with MS1. A range of different chemotherapy regimens were used in this series, which also included people with relapsing remitting MS, secondary progressive MS and primary progressive MS. This data suggests that in approximately 55% of MS patients at three years of follow-up, inflammatory disease was halted with no evidence during the follow-up period of relapses, active lesions or disability progression. After 5 years, approximately 45% of people remained progression free (no lesions, relapses or disability progression)1. Overall 13 of 345 (3.7%) people with MS treated between 1996 and 2007 died of transplanted related causes1.  In the acute 100 day post-transplant period, Transplant Related Mortality (TRM) was 2% for the entire series. However the 100 day TRM declined to 1.3% for people with MS treated between 2001 and 20077. TRM was closely related to the level of experience of the transplant centres1. The authors of the study were unable to draw any conclusions about the relative efficacy of the different chemotherapy regimens.

ASTIMS trial
The ASTIMS trial6, published in March 2015, compared AHSCT (using BEAM-ATG chemotherapy) to mitoxantrone (a potent immunosuppressive treatment sometimes used for the treatment of MS) in 21 people with relapsing remitting or secondary progressive MS. The trial showed AHSCT to have a significantly greater effect on reducing relapses and evidence of lesions on MRI compared to mitoxantrone. This trial did not show any reduction in disability.  Eight of the 11 people treated with mitoxantrone experienced adverse events. All of the nine people treated with AHSCT, experienced expected adverse events, including low white blood cell count, fever, low platelet counts, anemia and diarrhea. No transplant related deaths were recorded, however, four of the nine AHSCT patients experienced severe adverse events (two of which were described as life-threatening) including sepsis, severe infections and late or failed engraftment of the re-infused stem cells.

Swedish Case Series
A Swedish study published in February 20148 enrolled 48 people with MS to look at the safety and effectiveness outcomes of AHSCT using either BEAM-ATG or Cyclophosphamide-ATG regimens. 41 of these patients were followed for greater than one year and included 34 with relapsing remitting MS and 7 with progressive forms of MS. The patients were followed for an average of close to 4 years with some followed for up to 9 years. At 5 years of follow-up 87% of participants had not experienced a relapse and 77% had not progressed based on EDSS scores, 68% had no disease activity (no relapses, no new MRI lesions and no disability progression). This study showed a significant difference in outcomes for patients who had gadolinium enhancing lesions prior to treatment compared to those who did not (79% of those with such lesions had no disease activity vs 46% in those who did not). No differences in efficacy were apparent between the two chemotherapy regimens, but the numbers in the Cyclophosphamide-ATG group were too small to make a reliable comparison. No transplant related deaths were recorded in this study and no patient required treatment in the intensive care unit. Almost all patients experienced acute toxicity during the hospitalisation period, with the expected side effects of hair loss, anaemia, low white blood cell counts and low platelet counts and half experienced infections. Later adverse events, following release from hospital, included reactivation of herpes zoster viral infections (8 patients) and thyroid disease (4 patients).

HALT-MS trial
The three year interim data from the five year HALT-MS US trial was published in December 20149. 25 people with relapsing remitting MS were treated with a BEAM-ATG protocol. This study reported 78% of participants as ‘event-free’ after three years (defined as no relapse, no change in disability level and no new MRI lesions), and 58% at five years. At the three year time point, 91% of participants did not show any worsening of disability, whilst 86% of participants did not experience a clinical relapse. All participants experienced serious adverse events which required medical intervention in the first 100 days following transplant, most of which were related to blood and gastrointestinal systems. There was no transplant related mortality. Publication of the full results of this study is expected once five year follow-up has been completed for all patients.

Chicago case series
Dr Richard Burt and colleagues at Northwestern University, Chicago published their case series of 123 people with relapsing remitting MS and 28 people with secondary progressive in January 201510. Participants were treated with the non-myeloablative Cyclophosphamide-ATG regimen (129 patients) or with Cyclophosphamide-Alemtuzumab (22 patients). The study found that after one year, 57 of 112 patients showed some evidence of improvement in disability scores while 19 showed evidence of disease progression. 80% of the 36 participants who were followed for 4 years were relapse-free and 87% showed no progression of disability. At the time of publishing, only 27 patients had been followed for 5 years, but 14 of them showed evidence of improvement and 4 showed evidence of disease progression, the rest remained stable.

When relapsing remitting and progressive MS cases were analysed separately, the study identified that the improvements in disability were strongest in the participants with relapsing remitting MS with duration of disease less than ten years. There were no transplant related deaths. Four patients developed late reactivation of herpes zoster infection (shingles). Severely low platelet counts and thyroid dysfunction was recorded in 6.9% of patients treated with the Cyclophosphamide -ATG protocol and 22.7% of patients treated with the Cyclophosphamide -Alemtuzumab protocol.

This research group is now leading an international multi-centre randomised clinical trial of AHSCT in comparison to other MS therapies. The trial, known as MIST, has sites in USA, UK, Sweden and Brazil (more information here). Encouraging results for three of the patients from the UK arm of the MIST trial have been featured in the media, however, we await with great interest the full results of the trial, which has enrolled at least 100 patients and is due to be completed in 2017.

Russian case series
In February 2015, clinicians at the Pirogov National Medical Surgical Centre in Moscow published a case series of 99 patients with MS (43 relapsing remitting and 56 progressive MS) treated with a reduced-intensity BEAM-like regimen at the centre11. 83.3% of relapsing remitting patients remained ‘event free’ after an average of 4 years follow-up and 75.5% of progressive patients remained ‘event free’. Of patients followed up for 8 years, 16.7% showed progression of disease. Of the 64 patients followed for three years or more, 47% were described as having improved disability scores by at least 0.5 points. No deaths were recorded, but the paper did not include details of adverse events or the number of patients affected. We are aware that many overseas patients including Australians are also  treated at this centre and may receive a conditioning regimen that differs from the one described in this publication. Details of conditioning regimens used for overseas patients at this centre and treatment outcomes have not yet been published in the medical literature.

Canadian Clinical Trial
In June 2016, Canadian researchers published long term follow-up results of their multi-centre, single-arm (no randomisation and no comparison treatment) of 24 individuals who presented with highly inflammatory MS with frequent relapses that did not respond to available disease modifying therapies21. Participants were treated with intensive chemotherapy protocol of busulphan and cyclophosphamide. 69.9% of patients had an MS disease activity-free status (the absence of relapses, brain lesions or disability progression) at 3 years after undergoing treatment. Participants were also followed up over a longer period ranging from 4 to 13 years post-treatment (median 6.7 years). All 23 participants had complete elimination of relapses and no new brain lesions during the entire follow-up period. Although the rate of brain volume loss initially significantly increased for the first 6 months after the procedure, the rate of loss then slowed and stabilized in all participants to a rate comparable with normal ageing. 70% of participants also showed no evidence of disability progression over the longer-term follow-up. Approximately 40% of participants experienced improvements in disability, such as recovered vision, strength and improved movement coordination. One death was recorded for a participant who died of complications from liver failure as a result of the AHSCT procedure. Another participant required intensive care as a result of chemotherapy-related toxicity, but ultimately recovered. Some participants also experienced the expected post-transplant viral infections and subsequently recovered. At publication, this was the longest follow-up of patients who had undergone AHSCT for MS.


1. Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, Ouyang J, Kozak T, Moore J, Kötter I, Chesnel V, Marmont A, Gratwohl A, Saccardi R. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica. 2010 Feb;95(2):284-92. doi: 10.3324/haematol.2009.013458. Epub 2009 Sep 22. [View abstract]

2. Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, Denton C,Hawkey C, Labopin M, Mancardi G, Martin R, Moore JJ, Passweg J, Peters C, Rabusin M, Rovira M, van Laar JM, Farge D; EBMT Autoimmune Disease Working Party (ADWP); Paediatric Diseases Working Party (PDWP). Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012 Jun;47(6):770-90. doi:10.1038/bmt.2011.185. Epub 2011 Oct 17. [view abstract]

3. Pasquini MC, Voltarelli J, Atkins HL, Hamerschlak N, Zhong X, Ahn KW, Sullivan KM, Carrum G, Andrey J, Bredeson CN, Cairo M, Gale RP, Hahn T, Storek J, Horowitz MM, McSweeney PA, Griffith LM, Muraro PA, Pavletic SZ, Nash RA. Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2012 Oct;18(10):1471-8. doi: 10.1016/j.bbmt.2012.06.003. Epub 2012 Jun 13. [view abstract]

4. Australasian Bone Marrow Transplant Recipient Registry 2014, Australasian Bone Marrow Transplant Recipient Registry: Annual Data Summary 2013, ABMTRR, Darlinghurst, NSW, Australia [more information here]

5. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, Okamoto S, Seber A, Socie G, Szer J, Van Lint MT, Wingard JR, Tichelli A; Center for International Blood and Marrow Transplant Research (CIBMTR); American Society for Blood and Marrow Transplantation (ASBMT); European Group for Blood and Marrow Transplantation (EBMT); Asia-Pacific Blood and Marrow Transplantation Group (APBMT); Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ); East Mediterranean Blood and Marrow Transplantation Group (EMBMT),; Sociedade Brasileira de Transplante de Medula Ossea (SBTMO. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Mar;18(3):348-71. doi: 10.1016/j.bbmt.2011.12.519. Epub 2011 Dec 13. [view abstract]

6. Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E, Donelli A,Lugaresi A, Di Bartolomeo P, Rottoli MR, Rambaldi A, Amato MP, Massacesi L, Di Gioia M, Vuolo L, Currò D, Roccatagliata L, Filippi M, Aguglia U, Iacopino P,Farge D, Saccardi R; ASTIMS Haemato-Neurological Collaborative Group, On behalf of the Autoimmune Disease Working Party (ADWP) of the European Group for Blood and Marrow Transplantation (EBMT); ASTIMS Haemato-Neurological Collaborative Group On behalf of the Autoimmune Disease Working Party ADWP of the European Group for Blood and Marrow Transplantation EBMT. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015 Mar 10;84(10):981-8. doi: 10.1212/WNL.0000000000001329. Epub 2015 Feb 11. [view abstract]

7. Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 2008 Jul;7(7):626-36. doi:10.1016/S1474-4422(08)70138-8. Review. [view abstract]

8. Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, Vrethem M, Fredrikson S, Martin C, Sandstedt A, Uggla B, Lenhoff S, Johansson JE, Isaksson C, Hägglund H, Carlson K, Fagius J. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1116-21. doi: 10.1136/jnnp-2013-307207. Epub 2014 Feb 19. [view abstract

9. Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O, Arnold DL, Spychala ME, McConville KC, Harris KM, Phippard D, Georges GE, Wundes A, Kraft GH, Bowen JD. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015 Feb;72(2):159-69. doi: 10.1001/jamaneurol.2014.3780. [view abstract]

10. Burt RK, Balabanov R, Han X, Sharrack B, Morgan A, Quigley K, Yaung K, Helenowski IB, Jovanovic B, Spahovic D, Arnautovic I, Lee DC, Benefield BC, Futterer S, Oliveira MC, Burman J. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.JAMA. 2015 Jan 20;313(3):275-84. doi: 10.1001/jama.2014.17986. [view abstract]

11. Shevchenko JL, Kuznetsov AN, Ionova TI, Melnichenko VY, Fedorenko DA, Kurbatova KA, Gorodokin GI, Novik AA. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives. Ann Hematol. 2015 Jul;94(7):1149-57. doi: 10.1007/s00277-015-2337-8. Epub 2015 Feb 25. [view abstract]

12. Chen JT, Collins DL, Atkins HL, Freedman MS, Galal A, Arnold DL; Canadian MS BMT Study Group. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology. 2006 Jun 27;66(12):1935-7. [view abstract]

13. Roccatagliata L, Rocca M, Valsasina P, Bonzano L, Sormani M, Saccardi R, Mancardi G, Filippi M; Italian GITMO-NEURO Intergroup on Autologous Stem CellTransplantation. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Mult Scler. 2007 Sep;13(8):1068-70. Epub 2007 Apr 27. [view abstract]

14. Muraro PA, Robins H, Malhotra S, Howell M, Phippard D, Desmarais C, de Paula Alves Sousa A, Griffith LM, Lim N, Nash RA, Turka LA. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest. 2014 Mar;124(3):1168-72. doi: 10.1172/JCI71691. Epub 2014 Feb 17. [view abstract]

15. Loh Y, Oyama Y, Statkute L, Quigley K, Yaung K, Gonda E, Barr W, Jovanovic B,Craig R, Stefoski D, Cohen B, Burt RK. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases:role of conditioning regimen used. Blood. 2007 Mar 15;109(6):2643-548. Epub 2006 [view abstract]

16. Darlington PJ, Touil T, Doucet JS, Gaucher D, Zeidan J, Gauchat D, Corsini R, Kim HJ, Duddy M, Jalili F, Arbour N, Kebir H, Chen J, Arnold DL, Bowman M, Antel J, Prat A, Freedman MS, Atkins H, Sekaly R, Cheynier R, Bar-Or A; Canadian MS/BMT Study Group. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol. 2013 Mar;73(3):341-54. doi: 10.1002/ana.23784. Epub 2013 Mar 5. [view abstract]

17. Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, Land GA, Heslop H, Brenner M, Zhang JZ. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain 2004 May;127(Pt 5):996-1008. Epub 2004 Feb 25. [view abstract]

18. Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R, Campbell C, Memon S, Nagle JW, Hakim FT, Gress RE, McFarland HF, Burt RK, Martin R. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005 Mar 7;201(5):805-16. Epub 2005 Feb 28. [view abstract]

19. Rebeiro P, Moore J. The role of autologous haemopoietic stem cell transplantation in the treatment of autoimmune disorders. Intern Med J. 2015 Nov 2. doi: 10.1111/imj.12944. Epub ahead of print Review. [view abstract]

20. Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology. 2006 Aug 22;67(4):652-9. Epub 2006 Jul 26. PubMed PMID: 16870812. [view abstract]

21. Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny M, Hamelin L, Huebsch L, Hutton B, Laneuville P, Lapierre Y, Lee H, Martin L, McDiarmid S, O'Connor P, Ramsay T, Sabloff M, Walker L, Freedman MS. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. 2016 Jun 8. doi: 10.1016/S0140-6736(16)30169-6. Epub ahead of print [view abstract]

Further resources